Neuren Pharmaceuticals Limited (NEU.AX)
AUD 12.54
(-2.79%)
AUD 12.54
(-2.79%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 199.26 Million AUD | 12662.74% |
| 2022 | -1.58 Million AUD | 86.11% |
| 2021 | -8.22 Million AUD | -19.98% |
| 2020 | -8.8 Million AUD | 17.7% |
| 2019 | -11.07 Million AUD | -296.32% |
| 2018 | 5.36 Million AUD | 188.92% |
| 2017 | 2.73 Million AUD | 56.08% |
| 2016 | -13.77 Million AUD | 12.09% |
| 2015 | -14.05 Million AUD | -37.05% |
| 2014 | -8.21 Million AUD | -38.81% |
| 2013 | -9.02 Million AUD | 1.05% |
| 2012 | -4.76 Million AUD | -108.1% |
| 2011 | -4.41 Million AUD | 4.5% |
| 2010 | -4.58 Million AUD | -820.1% |
| 2009 | 481.62 Thousand AUD | 107.66% |
| 2008 | -14.26 Million AUD | 25.8% |
| 2007 | -11.16 Million AUD | 1.66% |
| 2006 | -11.39 Million AUD | -8.81% |
| 2005 | -9.69 Million AUD | -72.5% |
| 2004 | -6.06 Million AUD | -314.03% |
| 2003 | 2.83 Million AUD | 33.68% |
| 2002 | 2.12 Million AUD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 4.07 Million AUD | 0.0% |
| 2023 Q2 | 48.14 Million AUD | 0.0% |
| 2023 FY | - AUD | 12662.74% |
| 2023 Q4 | 151.09 Million AUD | 0.0% |
| 2022 Q4 | 5.74 Million AUD | 0.0% |
| 2022 FY | - AUD | 86.11% |
| 2022 Q2 | -7.33 Million AUD | 0.0% |
| 2021 Q2 | -8.19 Million AUD | 0.0% |
| 2021 FY | - AUD | -19.98% |
| 2021 Q4 | -3.22 Million AUD | 0.0% |
| 2020 FY | - AUD | 17.7% |
| 2020 Q2 | -5.31 Million AUD | 0.0% |
| 2020 Q4 | -4.2 Million AUD | 0.0% |
| 2019 FY | - AUD | -296.32% |
| 2019 Q2 | -7.9 Million AUD | 0.0% |
| 2019 Q4 | -3.66 Million AUD | 0.0% |
| 2018 Q4 | 9.74 Million AUD | 0.0% |
| 2018 FY | - AUD | 188.92% |
| 2018 Q2 | -3.85 Million AUD | 0.0% |
| 2017 Q2 | -3.43 Million AUD | 0.0% |
| 2017 Q4 | -2.56 Million AUD | 0.0% |
| 2017 FY | - AUD | 56.08% |
| 2016 Q2 | -8.11 Million AUD | 0.0% |
| 2016 FY | - AUD | 12.09% |
| 2016 Q4 | -3.82 Million AUD | 0.0% |
| 2015 Q4 | -9.01 Million AUD | 0.0% |
| 2015 FY | - AUD | -37.05% |
| 2015 Q2 | -6.47 Million AUD | 0.0% |
| 2014 Q2 | -4.39 Million AUD | 0.0% |
| 2014 Q4 | -5.23 Million AUD | 0.0% |
| 2014 FY | - AUD | -38.81% |
| 2013 Q4 | -3.5 Million AUD | -28.9% |
| 2013 FY | - AUD | 1.05% |
| 2013 Q3 | -2.71 Million AUD | 0.09% |
| 2013 Q2 | -2.72 Million AUD | -0.09% |
| 2013 Q1 | -2.71 Million AUD | 0.0% |
| 2012 Q2 | -1.18 Million AUD | 0.0% |
| 2012 Q3 | -1.18 Million AUD | 0.0% |
| 2012 FY | - AUD | -108.1% |
| 2012 Q4 | -2.71 Million AUD | -129.69% |
| 2012 Q1 | -1.18 Million AUD | 0.0% |
| 2011 Q3 | -1.07 Million AUD | 0.0% |
| 2011 Q1 | -1.07 Million AUD | 0.0% |
| 2011 Q2 | -1.07 Million AUD | 0.0% |
| 2011 FY | - AUD | 4.5% |
| 2011 Q4 | -1.18 Million AUD | -10.3% |
| 2010 Q3 | -1.12 Million AUD | 0.0% |
| 2010 Q1 | -1.12 Million AUD | 0.0% |
| 2010 Q4 | -1.07 Million AUD | 4.44% |
| 2010 FY | - AUD | -820.1% |
| 2010 Q2 | -1.12 Million AUD | 0.0% |
| 2009 Q2 | 151.97 Thousand AUD | 0.0% |
| 2009 Q4 | -1.12 Million AUD | -838.64% |
| 2009 Q1 | 151.97 Thousand AUD | 0.0% |
| 2009 Q3 | 151.97 Thousand AUD | 0.0% |
| 2009 FY | - AUD | 107.66% |
| 2008 Q2 | -3.55 Million AUD | 0.0% |
| 2008 Q3 | -3.55 Million AUD | 0.0% |
| 2008 Q4 | 151.97 Thousand AUD | 104.28% |
| 2008 FY | - AUD | 25.8% |
| 2008 Q1 | -3.55 Million AUD | 0.0% |
| 2007 Q3 | -2.8 Million AUD | 0.0% |
| 2007 Q1 | -2.8 Million AUD | 0.0% |
| 2007 FY | - AUD | 1.66% |
| 2007 Q4 | -3.55 Million AUD | -26.86% |
| 2007 Q2 | -2.8 Million AUD | 0.0% |
| 2006 Q4 | -2.8 Million AUD | -20.07% |
| 2006 Q3 | -2.33 Million AUD | 0.0% |
| 2006 FY | - AUD | -8.81% |
| 2006 Q1 | -2.33 Million AUD | 0.0% |
| 2006 Q2 | -2.33 Million AUD | 0.0% |
| 2005 Q1 | -1.87 Million AUD | 0.0% |
| 2005 Q2 | -1.87 Million AUD | 0.0% |
| 2005 Q3 | -1.87 Million AUD | 0.0% |
| 2005 Q4 | -2.33 Million AUD | -24.14% |
| 2005 FY | - AUD | -72.5% |
| 2004 Q2 | -2.6 Million AUD | 0.0% |
| 2004 FY | - AUD | -314.03% |
| 2004 Q4 | -1.87 Million AUD | 28.0% |
| 2004 Q1 | -2.6 Million AUD | 0.0% |
| 2004 Q3 | -2.6 Million AUD | 0.0% |
| 2003 Q1 | -2.69 Million AUD | 0.0% |
| 2003 Q3 | -2.69 Million AUD | 0.0% |
| 2003 FY | - AUD | 33.68% |
| 2003 Q4 | -2.6 Million AUD | 3.17% |
| 2003 Q2 | -2.69 Million AUD | 0.0% |
| 2002 FY | - AUD | 0.0% |
| 2002 Q1 | -2.59 Million AUD | 0.0% |
| 2002 Q2 | -2.59 Million AUD | 0.0% |
| 2002 Q3 | -2.59 Million AUD | 0.0% |
| 2002 Q4 | -2.69 Million AUD | -3.75% |
| 2001 Q4 | -2.59 Million AUD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| EZZ Life Science Holdings Limited | 10.37 Million AUD | -1820.511% |
| Anatara Lifesciences Ltd | -1.45 Million AUD | 13779.339% |
| Zelira Therapeutics Limited | -36.44 Million AUD | 646.804% |
| Biome Australia Limited | -1.57 Million AUD | 12725.495% |
| Patrys Limited | -3.49 Million AUD | 5805.993% |
| Orthocell Limited | -11.68 Million AUD | 1805.847% |
| Imugene Limited | -147.97 Million AUD | 234.657% |
| Noxopharm Limited | -5.94 Million AUD | 3451.482% |
| PYC Therapeutics Limited | -38.11 Million AUD | 622.757% |
| Chimeric Therapeutics Limited | -11.29 Million AUD | 1863.415% |
| Prescient Therapeutics Limited | -7.18 Million AUD | 2873.035% |
| Proteomics International Laboratories Limited | -7.88 Million AUD | 2626.358% |
| Cynata Therapeutics Limited | -9.95 Million AUD | 2102.592% |
| CSL Limited | 4.73 Billion AUD | 95.79% |
| Arovella Therapeutics Limited | -8.83 Million AUD | 2355.84% |
| Bio-Gene Technology Limited | -2.97 Million AUD | 6797.909% |
| Clinuvel Pharmaceuticals Limited | 51.86 Million AUD | -284.209% |
| Starpharma Holdings Limited | -12.57 Million AUD | 1684.336% |
| Nanollose Limited | -1.14 Million AUD | 17458.814% |
| Memphasys Limited | -3.3 Million AUD | 6124.148% |
| Invex Therapeutics Ltd | -720.44 Thousand AUD | 27758.337% |
| NeuroScientific Biopharmaceuticals Limited | -1.79 Million AUD | 11193.006% |
| Amplia Therapeutics Limited | -4.55 Million AUD | 4470.167% |
| Botanix Pharmaceuticals Limited | -13.91 Million AUD | 1531.544% |
| Island Pharmaceuticals Limited | -2.81 Million AUD | 7170.75% |
| Race Oncology Limited | -14.2 Million AUD | 1502.92% |
| Nyrada Inc. | -4.59 Million AUD | 4435.362% |
| Telix Pharmaceuticals Limited | 22.96 Million AUD | -767.639% |
| Dimerix Limited | -24.95 Million AUD | 898.372% |
| PharmAust Limited | -9.45 Million AUD | 2208.21% |
| Immutep Limited | -42.87 Million AUD | 564.749% |
| Clarity Pharmaceuticals Ltd | -44.64 Million AUD | 546.3% |
| Alterity Therapeutics Limited | -19.57 Million AUD | 1118.118% |
| BTC Health Limited | 1.05 Million AUD | -18782.257% |
| Acrux Limited | -7.93 Million AUD | 2612.445% |
| Biotron Limited | -5.04 Million AUD | 4053.569% |
| Tissue Repair Ltd | -5.77 Million AUD | 3550.427% |
| AdAlta Limited | -5.3 Million AUD | 3857.745% |
| Radiopharm Theranostics Limited | -45.37 Million AUD | 539.134% |
| Hexima Limited | -995.54 Thousand AUD | 20115.409% |
| AnteoTech Limited | -11.57 Million AUD | 1822.086% |
| Paradigm Biopharmaceuticals Limited | -64.53 Million AUD | 408.746% |
| Recce Pharmaceuticals Ltd | -21.35 Million AUD | 1033.132% |
| Avecho Biotechnology Limited | -3.24 Million AUD | 6245.301% |
| Actinogen Medical Limited | -12.92 Million AUD | 1642.136% |
| Immuron Limited | -6.19 Million AUD | 3317.87% |
| Argenica Therapeutics Limited | -1.89 Million AUD | 10600.788% |